Carbapenem-Resistant Pseudomonas aeruginosa Spondylodiscitis Treated with Ceftazidime-Avibactam: A Case Report with Literature Review

Pyogenic spondylodiscitis (PS) is a highly morbid and potentially fatal bacterial infection with an increasing incidence in recent decades. Its diagnosis and treatment are challenging, especially with the expansion of multidrug- or extensively drug-resistant bacteria. We report a rare case of PS cau...

Full description

Saved in:
Bibliographic Details
Published in:Infection and drug resistance 2023-09, Vol.16, p.5309-5317
Main Authors: Danda, Guilherme José da Nóbrega, Franco, Andreia Craveiro, Gomes, Elisangela Ana Paula, Montanaro, Vinícius Vianna Abreu, Martins, Bernardo José Alves Ferreira, Viana Bonan de Aguiar, Vitor
Format: Article
Language:English
Subjects:
Antibacterial agents
antibiotic
Bacteria
Bacterial infections
Beta lactamases
bone and joint infection
Care and treatment
Case Report
Ceftazidime
Diagnosis
Drug resistance in microorganisms
Health aspects
Infection
Methicillin
Pseudomonas aeruginosa
resistance
Sulbactam
vertebral osteomyelitis
β-lactam/β-lactamase inhibitor
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pyogenic spondylodiscitis (PS) is a highly morbid and potentially fatal bacterial infection with an increasing incidence in recent decades. Its diagnosis and treatment are challenging, especially with the expansion of multidrug- or extensively drug-resistant bacteria. We report a rare case of PS caused by carbapenem-resistant Pseudomonas aeruginosa (CRPA) that was treated with ceftazidime-avibactam (C/A). The choice of C/A therapy was based on the patient's bacterial sensitivity profile and intolerance to the initial therapeutic regimen (polymyxin B and meropenem). The total antimicrobial treatment time was seven weeks. The evolution of the clinical course met the cure criteria, which was characterized by remission of signs and symptoms, normalization of inflammatory markers, and radiological improvement over 18 months of clinical follow-up. This is a rare case of CRPA spondylodiscitis that responded to C/A treatment. Keywords: antibiotic, [beta]-lactam/[beta]-lactamase inhibitor, resistance, vertebral osteomyelitis, bone and joint infection
ISSN:1178-6973
1178-6973
DOI:10.2147/IDR.S421209